Sequencing:Article Title: Frog Skin Peptides: Nature's Dual-Action Weapons Against Infection and Cancer.
Article Snippet: .. Peptide Name and Sequence Frog Species Hydrophobic Residues (%) a 3D Structure a AC Activity AB Activity Ref. Frenatin 2.1S GLVGTLLGHIGKAILG Sphaenorhynchus lacteus 50 Helix A549 (LC50 80–140 μM) 4T1 (n.d.) S. aureus ATCC 25293 (MIC 8 μM) MRSA 127/08, 145/08, 274/08, S908, T4/6, V4180 clinical isolates (MIC 8–16 μM) S. epidermidis RP62A biofilm producer, RP62A/1 biofilm non-producer variant of RP62A, T6/19 and T37/8 clinical isolates (MIC 8–16 μM) E. coli ATCC 25726 (MIC 125 μM) K. pneumoniae ATCC 700603 (MIC 250 μM) P. aeruginosa ATCC 27853 (MIC 250 μM) E. faecalis ATCC 29212 (MIC 62.5 μM) A. baumannii NM8, NM35, NM75, NM109, NM124 clinical isolates (MIC 62.5–125 μM) S. maltophilia B32/1, B32/4, B5/5, B6/2, U8708 clinical isolates (MIC 31.3–62.5 μM) X. axonopodis pv. vesicatoria (MIC 3.1–6.2 μM) * [103,104] Frenatin 2.2S GLVGTLLGHIGKAILS Sphaenorhynchus lacteus 50 Helix A549 (LC50 65 μM) S. aureus ATCC 25293 (MIC 16 μM) MRSA 127/08, 145/08, 274/08, S908, T4/6, V4180 clinical isolates (MIC 8–16 μM) S. epidermidis RP62A biofilm producer, RP62A/1 biofilm non-producer variant of RP62A, T6/19 and T37/8 clinical isolates (MIC 8–16 μM) A. baumannii NM8, NM35, NM75, NM109, NM124 clinical isolates (MIC 62.5–125 μM) S. maltophilia B32/1, B32/4, B5/5, B6/2, U8708 clinical isolates (MIC 31.3–62.5 μM) E. coli ATCC 25726 (MIC 125 μM) K. pneumoniae ATCC 700603 (MIC 250 μM) P. aeruginosa ATCC 27853 (MIC 250 μM) E. faecalis ATCC 29212 (MIC 62.5 μM) X. axonopodis pv. vesicatoria (MIC 6.2–12.5 μM) * X. arboricola pv. pruni (MIC 6.2–12.5 μM) * [103] Hylin PL FLGLIPALAGAIGNLIK Boana platanera 65 Helix A549 (LC50 58 μg/mL) HT-29 (LC50 68 μg/mL) MDA-MB-231 (LC50 58 μg/mL) E. coli DSM 787 (MIC 100 μg/mL) S. aureus ATCC 43300 (MIC 100 μg/mL) S. epidermidis DSM 28319 (MIC > 100 μg/mL) P. aeruginosa DSM 50071 (MIC > 100 μg/mL) K. pneumoniae ATCC BAA1705 (MIC > 100 μg/mL) A. baumannii DSM 30008 (MIC 100 μg/mL) E. faecalis MF 06036 (MIC 100 μg/mL) E. faecium NCTC 12201 (MIC 50 μg/mL) C. difficile R20291 or 630 BAA1382 (MIC 25–50 μg/mL) [102] https://doi.org/10.3390/antibiotics15030324 Table 1. ..
Activity Assay:Article Title: Frog Skin Peptides: Nature's Dual-Action Weapons Against Infection and Cancer.
Article Snippet: .. Peptide Name and Sequence Frog Species Hydrophobic Residues (%) a 3D Structure a AC Activity AB Activity Ref. Frenatin 2.1S GLVGTLLGHIGKAILG Sphaenorhynchus lacteus 50 Helix A549 (LC50 80–140 μM) 4T1 (n.d.) S. aureus ATCC 25293 (MIC 8 μM) MRSA 127/08, 145/08, 274/08, S908, T4/6, V4180 clinical isolates (MIC 8–16 μM) S. epidermidis RP62A biofilm producer, RP62A/1 biofilm non-producer variant of RP62A, T6/19 and T37/8 clinical isolates (MIC 8–16 μM) E. coli ATCC 25726 (MIC 125 μM) K. pneumoniae ATCC 700603 (MIC 250 μM) P. aeruginosa ATCC 27853 (MIC 250 μM) E. faecalis ATCC 29212 (MIC 62.5 μM) A. baumannii NM8, NM35, NM75, NM109, NM124 clinical isolates (MIC 62.5–125 μM) S. maltophilia B32/1, B32/4, B5/5, B6/2, U8708 clinical isolates (MIC 31.3–62.5 μM) X. axonopodis pv. vesicatoria (MIC 3.1–6.2 μM) * [103,104] Frenatin 2.2S GLVGTLLGHIGKAILS Sphaenorhynchus lacteus 50 Helix A549 (LC50 65 μM) S. aureus ATCC 25293 (MIC 16 μM) MRSA 127/08, 145/08, 274/08, S908, T4/6, V4180 clinical isolates (MIC 8–16 μM) S. epidermidis RP62A biofilm producer, RP62A/1 biofilm non-producer variant of RP62A, T6/19 and T37/8 clinical isolates (MIC 8–16 μM) A. baumannii NM8, NM35, NM75, NM109, NM124 clinical isolates (MIC 62.5–125 μM) S. maltophilia B32/1, B32/4, B5/5, B6/2, U8708 clinical isolates (MIC 31.3–62.5 μM) E. coli ATCC 25726 (MIC 125 μM) K. pneumoniae ATCC 700603 (MIC 250 μM) P. aeruginosa ATCC 27853 (MIC 250 μM) E. faecalis ATCC 29212 (MIC 62.5 μM) X. axonopodis pv. vesicatoria (MIC 6.2–12.5 μM) * X. arboricola pv. pruni (MIC 6.2–12.5 μM) * [103] Hylin PL FLGLIPALAGAIGNLIK Boana platanera 65 Helix A549 (LC50 58 μg/mL) HT-29 (LC50 68 μg/mL) MDA-MB-231 (LC50 58 μg/mL) E. coli DSM 787 (MIC 100 μg/mL) S. aureus ATCC 43300 (MIC 100 μg/mL) S. epidermidis DSM 28319 (MIC > 100 μg/mL) P. aeruginosa DSM 50071 (MIC > 100 μg/mL) K. pneumoniae ATCC BAA1705 (MIC > 100 μg/mL) A. baumannii DSM 30008 (MIC 100 μg/mL) E. faecalis MF 06036 (MIC 100 μg/mL) E. faecium NCTC 12201 (MIC 50 μg/mL) C. difficile R20291 or 630 BAA1382 (MIC 25–50 μg/mL) [102] https://doi.org/10.3390/antibiotics15030324 Table 1. ..
Variant Assay:Article Title: Frog Skin Peptides: Nature's Dual-Action Weapons Against Infection and Cancer.
Article Snippet: .. Peptide Name and Sequence Frog Species Hydrophobic Residues (%) a 3D Structure a AC Activity AB Activity Ref. Frenatin 2.1S GLVGTLLGHIGKAILG Sphaenorhynchus lacteus 50 Helix A549 (LC50 80–140 μM) 4T1 (n.d.) S. aureus ATCC 25293 (MIC 8 μM) MRSA 127/08, 145/08, 274/08, S908, T4/6, V4180 clinical isolates (MIC 8–16 μM) S. epidermidis RP62A biofilm producer, RP62A/1 biofilm non-producer variant of RP62A, T6/19 and T37/8 clinical isolates (MIC 8–16 μM) E. coli ATCC 25726 (MIC 125 μM) K. pneumoniae ATCC 700603 (MIC 250 μM) P. aeruginosa ATCC 27853 (MIC 250 μM) E. faecalis ATCC 29212 (MIC 62.5 μM) A. baumannii NM8, NM35, NM75, NM109, NM124 clinical isolates (MIC 62.5–125 μM) S. maltophilia B32/1, B32/4, B5/5, B6/2, U8708 clinical isolates (MIC 31.3–62.5 μM) X. axonopodis pv. vesicatoria (MIC 3.1–6.2 μM) * [103,104] Frenatin 2.2S GLVGTLLGHIGKAILS Sphaenorhynchus lacteus 50 Helix A549 (LC50 65 μM) S. aureus ATCC 25293 (MIC 16 μM) MRSA 127/08, 145/08, 274/08, S908, T4/6, V4180 clinical isolates (MIC 8–16 μM) S. epidermidis RP62A biofilm producer, RP62A/1 biofilm non-producer variant of RP62A, T6/19 and T37/8 clinical isolates (MIC 8–16 μM) A. baumannii NM8, NM35, NM75, NM109, NM124 clinical isolates (MIC 62.5–125 μM) S. maltophilia B32/1, B32/4, B5/5, B6/2, U8708 clinical isolates (MIC 31.3–62.5 μM) E. coli ATCC 25726 (MIC 125 μM) K. pneumoniae ATCC 700603 (MIC 250 μM) P. aeruginosa ATCC 27853 (MIC 250 μM) E. faecalis ATCC 29212 (MIC 62.5 μM) X. axonopodis pv. vesicatoria (MIC 6.2–12.5 μM) * X. arboricola pv. pruni (MIC 6.2–12.5 μM) * [103] Hylin PL FLGLIPALAGAIGNLIK Boana platanera 65 Helix A549 (LC50 58 μg/mL) HT-29 (LC50 68 μg/mL) MDA-MB-231 (LC50 58 μg/mL) E. coli DSM 787 (MIC 100 μg/mL) S. aureus ATCC 43300 (MIC 100 μg/mL) S. epidermidis DSM 28319 (MIC > 100 μg/mL) P. aeruginosa DSM 50071 (MIC > 100 μg/mL) K. pneumoniae ATCC BAA1705 (MIC > 100 μg/mL) A. baumannii DSM 30008 (MIC 100 μg/mL) E. faecalis MF 06036 (MIC 100 μg/mL) E. faecium NCTC 12201 (MIC 50 μg/mL) C. difficile R20291 or 630 BAA1382 (MIC 25–50 μg/mL) [102] https://doi.org/10.3390/antibiotics15030324 Table 1. ..
Multiple Displacement Amplification:Article Title: Frog Skin Peptides: Nature's Dual-Action Weapons Against Infection and Cancer.
Article Snippet: .. Peptide Name and Sequence Frog Species Hydrophobic Residues (%) a 3D Structure a AC Activity AB Activity Ref. Frenatin 2.1S GLVGTLLGHIGKAILG Sphaenorhynchus lacteus 50 Helix A549 (LC50 80–140 μM) 4T1 (n.d.) S. aureus ATCC 25293 (MIC 8 μM) MRSA 127/08, 145/08, 274/08, S908, T4/6, V4180 clinical isolates (MIC 8–16 μM) S. epidermidis RP62A biofilm producer, RP62A/1 biofilm non-producer variant of RP62A, T6/19 and T37/8 clinical isolates (MIC 8–16 μM) E. coli ATCC 25726 (MIC 125 μM) K. pneumoniae ATCC 700603 (MIC 250 μM) P. aeruginosa ATCC 27853 (MIC 250 μM) E. faecalis ATCC 29212 (MIC 62.5 μM) A. baumannii NM8, NM35, NM75, NM109, NM124 clinical isolates (MIC 62.5–125 μM) S. maltophilia B32/1, B32/4, B5/5, B6/2, U8708 clinical isolates (MIC 31.3–62.5 μM) X. axonopodis pv. vesicatoria (MIC 3.1–6.2 μM) * [103,104] Frenatin 2.2S GLVGTLLGHIGKAILS Sphaenorhynchus lacteus 50 Helix A549 (LC50 65 μM) S. aureus ATCC 25293 (MIC 16 μM) MRSA 127/08, 145/08, 274/08, S908, T4/6, V4180 clinical isolates (MIC 8–16 μM) S. epidermidis RP62A biofilm producer, RP62A/1 biofilm non-producer variant of RP62A, T6/19 and T37/8 clinical isolates (MIC 8–16 μM) A. baumannii NM8, NM35, NM75, NM109, NM124 clinical isolates (MIC 62.5–125 μM) S. maltophilia B32/1, B32/4, B5/5, B6/2, U8708 clinical isolates (MIC 31.3–62.5 μM) E. coli ATCC 25726 (MIC 125 μM) K. pneumoniae ATCC 700603 (MIC 250 μM) P. aeruginosa ATCC 27853 (MIC 250 μM) E. faecalis ATCC 29212 (MIC 62.5 μM) X. axonopodis pv. vesicatoria (MIC 6.2–12.5 μM) * X. arboricola pv. pruni (MIC 6.2–12.5 μM) * [103] Hylin PL FLGLIPALAGAIGNLIK Boana platanera 65 Helix A549 (LC50 58 μg/mL) HT-29 (LC50 68 μg/mL) MDA-MB-231 (LC50 58 μg/mL) E. coli DSM 787 (MIC 100 μg/mL) S. aureus ATCC 43300 (MIC 100 μg/mL) S. epidermidis DSM 28319 (MIC > 100 μg/mL) P. aeruginosa DSM 50071 (MIC > 100 μg/mL) K. pneumoniae ATCC BAA1705 (MIC > 100 μg/mL) A. baumannii DSM 30008 (MIC 100 μg/mL) E. faecalis MF 06036 (MIC 100 μg/mL) E. faecium NCTC 12201 (MIC 50 μg/mL) C. difficile R20291 or 630 BAA1382 (MIC 25–50 μg/mL) [102] https://doi.org/10.3390/antibiotics15030324 Table 1. ..
other:
|